Biomatter’s cover photo
Biomatter

Biomatter

Biotechnology Research

Vilnius, Vilnius County 4,841 followers

Creating proteins with Intelligent Architecture™ for health and sustainable manufacturing

About us

Biomatter (previously called Biomatter Designs) is a synthetic biology company that creates new proteins for health and sustainable manufacturing applications. The company has developed the Intelligent Architecture™ platform that addresses limitations of current engineering approaches to unlock completely new horizons for protein design and development.

Website
http://www.biomatter.ai
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Vilnius, Vilnius County
Type
Privately Held
Founded
2018
Specialties
biocatalysis, enzyme design, enzyme optimization, enzyme discovery, enzyme engineering, biocatalysts, life sciences, api manufacturing, chemical manufacturing, synthetic biology, biomanufacturing, protein design, and protein engineering

Locations

Employees at Biomatter

Updates

  • Thanks to BIOCONNECT for creating this sneak peek into the world of enzyme development! #Biomatter #ProteinArchitects #EnzymeDevelopment #IntelligentArchitecture

    View organization page for BIOCONNECT

    491 followers

    In the BIOCONNECT project, we continue our journey by presenting the third company – Biomatter from Lithuania. 🧪 𝐑𝐞𝐢𝐦𝐚𝐠𝐢𝐧𝐢𝐧𝐠 𝐄𝐧𝐳𝐲𝐦𝐞 𝐃𝐞𝐬𝐢𝐠𝐧 𝐰𝐢𝐭𝐡 Biomatter Biomatter is transforming enzyme innovation with generative AI, creating entirely new-to-nature enzymes from scratch. By starting with first principles and using a platform trained on billions of natural enzyme sequences, Biomatter accelerates development cycles from years to weeks. This groundbreaking approach not only unlocks unprecedented possibilities in enzyme functionality but also paves the way for solutions to some of the world’s most pressing challenges in health and sustainability. #BiotechInnovation #GenerativeAI #EnzymeDesign #Sustainability #HealthTech

  • We are thrilled to share that the Artificial Intelligence Association of Lithuania recognized us as the AI Company of the Year 2024 🚀 This award highlights our innovative bottom-up approach to enzyme design, which enables the creation of perfect enzymes with atomic-level precision. It advances the frontiers of enzyme engineering and redefines the boundaries of what's possible in enzyme development. We're excited to see what new opportunities 2025 will bring! 🌟 #Biomatter #ProteinArchitects #IntelligentArchitecture #EnzymeDesign #EnzymeEngineering

    View profile for Laurynas Karpus

    CEO & Co-Founder at Biomatter | Creating proteins with Intelligent Architecture™

    What a fantastic start to 2025! Biomatter is honored to be named the AI Company of the Year 2024 at the Artificial Intelligence Association of Lithuania. This award recognizes Biomatter's pioneering work in AI for synthetic biology through our Intelligent Architecture™ platform, which combines Generative AI and Physics-based modeling for advanced enzyme development. This achievement reflects years of dedication from the entire Biomatter team, whose expertise and commitment continue to drive global innovation in this field. As we begin 2025, we look forward to further advancing protein engineering and unlocking new possibilities in synthetic biology!

    • No alternative text description for this image
  • Biomatter is heading to Sweden for #BioEurope2024! We're looking forward to connecting with industry leaders and exchanging the latest insights in the biotech field. Indrė will be there to explore how Biomatter can support streamlining enzyme-based processes or drive forward new product ideas. Make sure to reach out and find a time to meet her! #Biomatter #ProteinArchitects #IntelligentArchitecture #EnzymeDevelopment #EnzymeOptimization #EnzymeEngineering

    • No alternative text description for this image
  • Biomatter reposted this

    Throwback to last week… and WOW 🤩 #InvestorCamp and #StartupFair had us absolutely buzzing. From panels, nonstop networking, startup pitches, and yes, gin-infused drinks — the energy was OFF THE CHARTS. 💥 Here’s the tea: ✨ Investor Camp: Donatas Keras sat down with Juozas Nainys and Laurynas Karpus to talk life sciences + AI (and blew our minds) x Atrandi Biosciences x Biomatter  ✨ Practica’s Aperitif? Drinks + vibes on point.  ✨ Investor Camp Dinner - conversations flowing, connections made.  ✨ Next day = all about startups. Arvydas Bloze hit the stage with Justinas Baranovskis to share the deets on their fresh Series B round x Ovoko \ RRR.LT ✨ Wrapped up with the ultimate Founders & Funders party — over 100 guests, co-hosted with FIRSTPICK, Earlybird Digital East Fund, and Northzone. Unreal. 📷 Here are some moments we've made together: https://lnkd.in/gm3WttVN Huge shoutout to all our friends & partners Lithuanian Private Equity and Venture Capital Association, Startup Lithuania, Lithuanian Business Angel Network LitBAN, and every single person we met. ❤️ Catch you at the next one.

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +5
  • Exciting news from the world of computational protein engineering! The 2024 Nobel Prize in Chemistry has been awarded to David Baker, Demis Hassabis, and John M. Jumper for their pioneering contributions to protein design and structure prediction. Their work is transforming how we understand and manipulate proteins, creating entirely new possibilities in medicine, materials science, and beyond. 🚀 We couldn't be more inspired by this achievement, which points to a future where biology is reshaped by engineering proteins, including enzymes, playing a crucial role across industries - from pharmaceuticals and chemical manufacturing to food or life sciences. We're excited to be a part of this computational protein engineering journey, pushing the boundaries of enzyme development whilst creating a more sustainable and healthier world.

    View organization page for The Nobel Prize

    1,017,410 followers

    BREAKING NEWS The Royal Swedish Academy of Sciences has decided to award the 2024 Nobel Prize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.”   The Nobel Prize in Chemistry 2024 is about proteins, life’s ingenious chemical tools. David Baker has succeeded with the almost impossible feat of building entirely new kinds of proteins. Demis Hassabis and John Jumper have developed an AI model to solve a 50-year-old problem: predicting proteins’ complex structures. These discoveries hold enormous potential.   The diversity of life testifies to proteins’ amazing capacity as chemical tools. They control and drive all the chemical reactions that together are the basis of life. Proteins also function as hormones, signal substances, antibodies and the building blocks of different tissues.   Proteins generally consist of 20 different amino acids, which can be described as life’s building blocks. In 2003, David Baker succeeded in using these blocks to design a new protein that was unlike any other protein. Since then, his research group has produced one imaginative protein creation after another, including proteins that can be used as pharmaceuticals, vaccines, nanomaterials and tiny sensors.   The second discovery concerns the prediction of protein structures. In proteins, amino acids are linked together in long strings that fold up to make a three-dimensional structure, which is decisive for the protein’s function. Since the 1970s, researchers had tried to predict protein structures from amino acid sequences, but this was notoriously difficult. However, four years ago, there was a stunning breakthrough.   In 2020, Demis Hassabis and John Jumper presented an AI model called AlphaFold2. With its help, they have been able to predict the structure of virtually all the 200 million proteins that researchers have identified. Since their breakthrough, AlphaFold2 has been used by more than two million people from 190 countries. Among a myriad of scientific applications, researchers can now better understand antibiotic resistance and create images of enzymes that can decompose plastic.   Life could not exist without proteins. That we can now predict protein structures and design our own proteins confers the greatest benefit to humankind. Learn more Press release: https://bit.ly/3TM8oVs Popular information: https://bit.ly/3XYHZGp Advanced information: https://bit.ly/4ewMBta

    • No alternative text description for this image
  • Biomatter team is heading to London this week! 🇬🇧 We're excited to dive into how protein-powered technologies are shaping a more sustainable, efficient food system while also driving innovation in novel food ingredients space. Our team members, Matthew and Ieva, are eager to connect and discuss how our Intelligent Architecture can help tackle enzyme-related challenges in the food industry. Let's connect and have a chat! #FutureFoodTech #EnzymeEngineering #IntelligentArchitecture #EnzymeDesign #Biomatter #ProteinArchitects

    • No alternative text description for this image
  • Biomatter reposted this

    Get Ready for Investor Camp Next Week! 🚀 We’re excited to introduce one of the panels: The Intersection of Life Sciences and AI — a deep dive into one of the most groundbreaking and transformative fields today. This is your opportunity to hear directly from visionary founders who are shaping the future of healthcare, biotechnology, and artificial intelligence. Discover how these industries are converging to fuel game-changing innovations. 🔥 Meet the Panelists: Juozas Nainys, Co-Founder & CEO at Atrandi Biosciences Laurynas Karpus, Co-Founder & CEO at Biomatter The discussion will be moderated by our partner, Donatas Keras. 👉 Get your ticket: https://lnkd.in/dvyHuiiP P.S. As the event comes to a close, we'll invite all attendees for a pre-dinner networking gathering in a relaxed, informal setting - Aperitif by Practica. Looking forward to seeing you there! 👋

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • 📣 Biomatter raises a €6.5 million round to unlock the power of generative AI for enzyme design 🎉 At Biomatter, we believe that the limitless potential to design new enzymes will contribute to building a better future for everyone. The new funding brings us one step closer to realizing our vision. We are excited to announce the new €6.5 million financing round to further expand the unique capabilities of our platform and create new-to-world enzymes. This achievement would not have been possible without the incredible dedication of the entire Protein Architects team at Biomatter, who consistently go above and beyond to reimagine what's possible with enzymes. The investment round was led by Inventure and UVC Partners, joined by existing investors Practica Capital and Metaplanet, as well as esteemed business angels and industry experts. For more insights, check out the article from SynBioBeta in the comments. #Biomatter #ProteinaArchitects #EnzymeDevelopment

    • No alternative text description for this image

Similar pages